MedTrace Logo

Donepezil Treatment for Sleep Apnea Patients

NCT00912457 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-06-03

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of the anticholinesterase drug donepezil on sleep apnea patients. Sleep structure and respiratory parameters will be analyzed by polysomnography.

Conditions

Interventions

DRUG

donepezil

donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days

DRUG

placebo

placebo 1 p/day for 28 days

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • Associacao Fundo de Incentivo a Psicofarmcologia

    lead OTHER

Principal Investigators

  • Walter Moraes, MD PhD · Associacao Fundo de Incentivo a Psicofarmcologia

  • Lucia Sukys-Claudino, MD · AFIP / UNIFESP

  • Dalva Poyares, MD, PhD · AFIP/ UNIFESP

  • Sergio Tufik, MD, PhD · AFIP/ UNIFESP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912457 on ClinicalTrials.gov